ProAxsis Ltd CEO Update Report – End Q4 2021

PR8

ProAxsis Ltd CEO Update Report – End Q4 2021 WP_Developer May 20, 2022 Recent Posts NetScientific acquires 100% control of portfolio company ProAxsis LimitedMay 20, 2022 ProAxsis Limited appoints distributor for key North America regionMay 20, 2022 ProAxsis Limited appoints first distributor for DACH regionMay 20, 2022 Have Any Questions? Lorem ipsum dolor sit amet […]

ProAxsis Limited appoints first distributor for DACH region

PR5

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that it has appointed Hölzel Diagnostika as the first distributor of its portfolio of respiratory research assays in Europe. Based in Cologne and founded in 1993, Hölzel Diagnostika specialises in the commercialisation of high-quality laboratory […]

ProAxsis Limited appoints distributor for key North America region

PR4

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that it has appointed Diapharma Group Inc. as the exclusive distributor of its portfolio of respiratory research assays for the North America region. Based in Ohio, Diapharma has specialised in the commercialisation of products within […]

NetScientific acquires 100% control of portfolio company ProAxsis Limited

PR6

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces a significant change to its investor base. Netscientific, who previously held a 56.4% equity share of ProAxsis, have taken full control of the company through acquisition of all the remaining shares via the execution of […]

ProAxsis investing in R&D to create new diagnostic tests for chronic human diseases

PR12

Belfast based respiratory diagnostics company, ProAxsis is investing over £200,000 in R&D to enhance its novel ProteaseTag® technology. The company is using Invest Northern Ireland’s support for R&D to develop new diagnostic biomarker tests which will help to identify critical signs of clinical deterioration for patients suffering with chronic diseases. Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, […]

ProAxsis and the Connected Health Innovation Centre launch new partnership

PR9

ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, today announces that it will be conducting a collaborative 12-month project with the Northern Ireland Connected Health Innovation Centre (CHIC), based at Ulster University. The project will focus on the development of a quantitative lateral flow device designed to monitor the ongoing clinical status of patients with respiratory diseases […]

ProAxsis and Ulster University initiate new partnership

PR11

ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, today announces that it will be conducting a collaborative 12-month project with the Northern Ireland Connected Health Innovation Centre (CHIC), based at Ulster University. The project will focus on the development of a quantitative lateral flow device designed to monitor the ongoing clinical status of patients with respiratory diseases […]

ProAxsis announces new appointments

PR8

ProAxsis Limited, the Belfast-based diagnostics company, is pleased to welcome back Elisha Cain, who re-joins the company in the newly created position of Quality Management Officer. Elisha previously completed her industrial placement year at ProAxsis, and recently gained a First Class honours degree in Stratified Medicine from Ulster University.  Elisha started her new role on […]

New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases

NEATstik packaging

Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the British Lung Foundation (BLF) and the European Respiratory Society (ERS), has been published in the latest edition of the European Respiratory Journal2 and demonstrates the potential for NEATstik®, a point-of-care test developed by Belfast-based ProAxsis Limited (www.proaxsis.com), to be used […]

ProAxsis enhances portfolio with new CE Marked Immunoassay

PR8

ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces that it has successfully registered a CE Mark for its novel ProteaseTag® Active Proteinase 3 Immunoassay. Furthermore, the company confirms an immediate first commercial sale for this new immunoassay. Proteinase 3 is a […]